Current issues in immunisation (Moving the second dose of measles-mumps-rubella vaccine to school entry: implications for control of rubella)
DOI:
https://doi.org/10.33321/cdi.1998.22.37Keywords:
measles-mumps-rubella vaccine, measles control, school entryAbstract
This article discusses the implications for the control of rubella resulting from changing the immunisation schedule for the second dose of the measles-mumps-rubella vaccine.
Downloads
References
Centers for Disease Control and Prevention. Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR 1998;47(RR-8):7.
de Quadros CA, Olive JM, Hersh BS, et al. Measles elimination in the Americas. Evolving strategies. JAMA 1996; 275:224-229.
Miller E. Measles, mumps and rubella: present and future immunisation policy. Public Health 1988; 102: 317-321.
Horstmann DM, Schluederberg A, Emmons JE, Evans BK, Randolph MF, Andiman WA. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 1985;7 Suppl 1:S80-5.
Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996;15:687-692.
Christenson B, Bottiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994;12:129-133.
Robertson SE, Cutts FT, Samuel R, Diaz-Ortega JL. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Bulletin of the World Health Organization 1997;75:69-80.
Bottiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine 1997;15:1538-1544.
Ukkonen P. Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979-1992. Scandinavian J Infect Dis 1996;28:31-35.
Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994;331:1397-1402.
Anonymous. Rubella and congenital rubella syndrome-United States, 1994-1997. MMWR 1997;46:350-354.
Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997;100:767-771.
Polk BF, Modlin JF, White JA, DeGirolami PC. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982;115:19-25.
Weibel RE, Stokes J Buynak EB, Hilleman MR. Live rubella vaccines in adults and children. Am J Dis Child 1969;118:226-229.
Condon RJ, Bower C. Rubella vaccination and congenital rubella syndrome in Western Australia. Med J Aust 1993;158:379-382.
National Health and Medical Research Council. Rubella. In: The Australian Immunisation Handbook, 6th Ed. Canberra: Australian Government Publishing Service, 1997:94.
Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiology and Infection 1995;115:139-156.
Australian Paediatric Surveillance Unit. Congenital rubella. 5th Annual Report, 1997. The New Children's Hospital, Sydney, 1998:in press.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 1998 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
